Budget Impact Analysis of Bevacizumab and Anti-Egfr with Chemotherapy for First and Second Line Treatment of Metastatic Colorectal Cancer in Russian Federation
May 1, 2014, 00:00
10.1016/j.jval.2014.03.437
https://www.valueinhealthjournal.com/article/S1098-3015(14)00488-4/fulltext
Title :
Budget Impact Analysis of Bevacizumab and Anti-Egfr with Chemotherapy for First and Second Line Treatment of Metastatic Colorectal Cancer in Russian Federation
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)00488-4&doi=10.1016/j.jval.2014.03.437
First page :
A75
Section Title :
Cancer
Open access? :
No
Section Order :
1484